Source comparison
Comparison: Sermorelin vs Other Peptides for Dermal Research
Sermorelin Acetate GHRH receptor agonist → pulsatile GH release → hepatic IGF-1 synthesis Indirect via systemic IGF-1 upregulation of fibroblast collagen transcription Small observational studies, no RCTs Fully reversible within 4–6 weeks of cessation Upstream
This comparison does not assign a generated winner or score.
- Sermorelin Acetate
- GHRH receptor agonist → pulsatile GH release → hepatic IGF-1 synthesis
- Indirect via systemic IGF-1 upregulation of fibroblast collagen transcription
- Small observational studies, no RCTs
- Fully reversible within 4–6 weeks of cessation
- Upstream neuroendocrine approach with consistent preclinical support but limited human validation
- GHK-Cu (Copper Peptide)
- Direct fibroblast activation, TGF-β signalling, matrix metalloproteinase modulation
- Direct collagen and elastin gene upregulation in dermal fibroblasts
- Multiple small RCTs for topical formulations
- Partially sustained (structural remodelling persists longer)
- Well-documented for topical use; systemic delivery less studied
- Matrixyl (Palmitoyl Pentapeptide)
- Mimics collagen fragments to trigger repair signalling
- Direct stimulation of collagen I, III, and IV synthesis via integrin receptors
- Multiple cosmetic RCTs, primarily topical
- Effect sustained for 8–12 weeks post-treatment
- Strong cosmetic evidence but lower biological potency than systemic IGF-1 pathway
- CJC-1295/Ipamorelin
- GHRH analogue + GHRP combination for sustained GH elevation
- Indirect via prolonged IGF-1 elevation (CJC has 6–8 day half-life vs sermorelin's 10 minutes)
- Observational data only, often combined with sermorelin
- Reversible but slower decline due to DAC modification
- Longer IGF-1 exposure window may enhance dermal effects vs sermorelin pulses